RESIC: A Tool for Comprehensive Adenosine to Inosine RNA Editing Site Identification and Classification.
ADAR
SARS-CoV-2
epitranscriptome
hyper-editing
interferon
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
03
2021
accepted:
07
06
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Adenosine to inosine (A-to-I) RNA editing, the most prevalent type of RNA editing in metazoans, is carried out by adenosine deaminases (ADARs) in double-stranded RNA regions. Several computational approaches have been recently developed to identify A-to-I RNA editing sites from sequencing data, each addressing a particular issue. Here, we present RNA Editing Sites Identification and Classification (RESIC), an efficient pipeline that combines several approaches for the detection and classification of RNA editing sites. The pipeline can be used for all organisms and can use any number of RNA-sequencing datasets as input. RESIC provides (1) the detection of editing sites in both repetitive and non-repetitive genomic regions; (2) the identification of hyper-edited regions; and (3) optional exclusion of polymorphism sites to increase reliability, based on DNA, and ADAR-mutant RNA sequencing datasets, or SNP databases. We demonstrate the utility of RESIC by applying it to human, successfully overlapping and extending the list of known putative editing sites. We further tested changes in the patterns of A-to-I RNA editing, and RNA abundance of ADAR enzymes, following SARS-CoV-2 infection in human cell lines. Our results suggest that upon SARS-CoV-2 infection, compared to mock, the number of hyper editing sites is increased, and in agreement, the activity of ADAR1, which catalyzes hyper-editing, is enhanced. These results imply the involvement of A-to-I RNA editing in conceiving the unpredicted phenotype of COVID-19 disease. RESIC code is open-source and is easily extendable.
Identifiants
pubmed: 34367244
doi: 10.3389/fgene.2021.686851
pmc: PMC8343188
doi:
Types de publication
Journal Article
Langues
eng
Pagination
686851Informations de copyright
Copyright © 2021 Light, Haas, Yazbak, Elfand, Blau and Lamm.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nucleic Acids Res. 2014 Jan;42(Database issue):D109-13
pubmed: 24163250
BMC Bioinformatics. 2017 Jan 3;18(1):7
pubmed: 28049429
Nucleic Acids Res. 2009 Nov;37(20):6905-15
pubmed: 19740767
Biol Rev Camb Philos Soc. 2012 Feb;87(1):95-110
pubmed: 21682836
Biomed J. 2013 Nov-Dec;36(6):259-68
pubmed: 24385067
Nat Biotechnol. 2004 Aug;22(8):1001-5
pubmed: 15258596
BMC Med Genomics. 2015;8 Suppl 2:S8
pubmed: 26043858
Nat Struct Mol Biol. 2011 Feb;18(2):230-6
pubmed: 21258325
BMC Genomics. 2013 Mar 27;14:206
pubmed: 23537002
Front Endocrinol (Lausanne). 2018 Dec 18;9:762
pubmed: 30619092
BMC Genomics. 2010 Jul 28;11:453
pubmed: 20667096
Nat Rev Genet. 2011 Nov 29;13(1):36-46
pubmed: 22124482
Science. 2012 Mar 16;335(6074):1302; author reply 1302
pubmed: 22422962
Cell Rep. 2021 Jan 12;34(2):108628
pubmed: 33440148
Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12174-9
pubmed: 20566853
Nat Struct Mol Biol. 2010 Sep;17(9):1043-50
pubmed: 20694008
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W115-22
pubmed: 23794635
EMBO Rep. 2005 Sep;6(9):831-5
pubmed: 16138094
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Methods. 2019 Mar 1;156:25-31
pubmed: 30465820
Genome Biol. 2014;15(12):550
pubmed: 25516281
Gigascience. 2016 Aug 18;5(1):37
pubmed: 27538485
Cell Rep. 2014 Nov 20;9(4):1482-94
pubmed: 25456137
PLoS Biol. 2004 Dec;2(12):e391
pubmed: 15534692
Open Biol. 2017 May;7(5):
pubmed: 28566301
Nat Methods. 2013 Feb;10(2):128-32
pubmed: 23291724
Genome Res. 2004 Sep;14(9):1719-25
pubmed: 15342557
Genome Res. 2017 Mar;27(3):462-470
pubmed: 28031250
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Hum Mutat. 2011 Nov;32(11):1268-77
pubmed: 21793106
Nat Rev Genet. 2018 Aug;19(8):473-490
pubmed: 29692414
Genome Res. 2004 Dec;14(12):2379-87
pubmed: 15545495
Trends Biochem Sci. 2021 Mar 15;:
pubmed: 33736931
Nat Commun. 2014 Aug 27;5:4726
pubmed: 25158696
Science. 2011 Jul 1;333(6038):53-8
pubmed: 21596952
Nat Struct Mol Biol. 2011 Sep 11;18(10):1094-101
pubmed: 21909095
RNA Biol. 2006 Jan-Mar;3(1):1-9
pubmed: 17114938
Sci Rep. 2015 Oct 09;5:14941
pubmed: 26449202
Front Immunol. 2020 Dec 10;11:598444
pubmed: 33362782
Genome Res. 2014 Mar;24(3):365-76
pubmed: 24347612
Bioinformatics. 2013 Jul 15;29(14):1813-4
pubmed: 23742983
Science. 2015 Sep 4;349(6252):1115-20
pubmed: 26275108
Semin Cell Dev Biol. 2012 May;23(3):244-50
pubmed: 21930228
PLoS One. 2010 Jun 21;5(6):e11173
pubmed: 20574523
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nat Methods. 2015 Apr;12(4):347-50
pubmed: 25730491
RNA Biol. 2017 Dec 2;14(12):1690-1694
pubmed: 28820319
Annu Rev Immunol. 2014;32:513-45
pubmed: 24555472
J Virol. 2013 Jan;87(2):1242-51
pubmed: 23152520
Drug Resist Updat. 2017 May;32:16-22
pubmed: 29145975